3-甲氧基苯乙酸甲酯 | 18927-05-4

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-甲氧基苯乙酸甲酯
• 中文别名: 2-(3-甲氧基苯基)乙酸甲酯
• 英文名称: methyl (3-methoxyphenyl)acetate
• 英文别名: methyl 2-(3-methoxyphenyl)acetate；(3-methoxy-phenyl)-acetic acid methyl ester
• CAS: 18927-05-4
• 化学式: C₁₀H₁₂O₃
• mdl: MFCD00017205
• 分子量: 180.203
• InChiKey: BSVIOYCZTJRBDB-UHFFFAOYSA-N

物化性质

• 沸点：
  80 °C
• 密度：
  1.12
• 闪点：
  86-88°C/0.5mm
• 保留指数：
  1380;1380
• 稳定性/保质期：

  常温常压下稳定，避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38,R20
• WGK Germany：
  -
• RTECS号：
  XR2275000
• 海关编码：
  2918990090
• 危险性防范说明：
  P264,P270,P301+P312,P330
• 危险性描述：
  H302
• 储存条件：
  常温下应密闭避光保存，并保持通风和干燥。

SDS

Name:	Methyl 2-(3-methoxyphenyl)acetate 97% Material Safety Data Sheet
Synonym:
CAS:	18927-05-4

Section 1 - Chemical Product MSDS Name:Methyl 2-(3-methoxyphenyl)acetate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
18927-05-4	Methyl 2-(3-methoxyphenyl)acetate, 97%	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 18927-05-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless - pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 86 - 88 deg C @0.5mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H12O3
Molecular Weight: 180

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 18927-05-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 2-(3-methoxyphenyl)acetate, 97% - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 18927-05-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 18927-05-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 18927-05-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲氧基苯乙酸甲酯 在 氯化亚砜 、 lithium hydroxide monohydrate 、 水 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 3-甲氧基苯基乙酰氯
  参考文献：
  名称：

  闭环烯烃-烯烃交叉偶联反应合成大内酰胺

  摘要：

  本文报道的是一种通过Rh（III）催化的闭环烯烃-烯烃交叉偶联反应合成大内酰胺的实用方法。反应是通过Rh催化的烯基sp 2 C–H活化过程进行的，该过程允许接触不同环大小的大环分子。含有共轭二烯骨架的大内酰胺可以很容易地以高化学选择性和Z，E立体选择性制备。

  DOI：

  10.1021/acs.orglett.0c03801
• 作为产物：
  描述：

  间甲基苯甲醚 在 sodium t-butanolate 作用下， 以 乙醚 为溶剂， 反应 10.0h， 生成 3-甲氧基苯乙酸甲酯
  参考文献：
  名称：

  烷氧基对苯和甲苯动力学和热力学酸性的影响

  摘要：

  2-，3-和4-甲氧基甲苯，可以选择性地在金属化ö -adjacent邻位置时丁基锂或叔在钠（钾）的存在下叔丁基锂叔丁醇或N，N，N'，N“，N” -五甲基二亚乙基三胺用作试剂。相反，二异丙基氨基化锂或2,2,6,6-四甲基哌啶锂仅使2-和3-甲氧基甲苯的苄基α-位质子去质子化，并优先使4-甲氧基甲苯的苄基α-位去质子化。这些相对的反应性可以通过过渡态稳定和不稳定力的相互作用来合理化（偶极匹配和金属配位与孤对排斥）。

  DOI：

  10.1016/s0040-4020(98)83011-1

文献信息

• Room Temperature Coupling of Aryldiazoacetates with Boronic Acids Enhanced by Blue Light Irradiation
  作者：Amanda F. Silva、Marco A. S. Afonso、Rodrigo A. Cormanich、Igor D. Jurberg

  DOI：10.1002/chem.201905812

  日期：2020.5.4

  visible-light-promoted photochemical protocol is reported for the coupling of aryldiazoacetates with boronic acids. This photochemical reaction shows great enhancement compared to the same protocol performed in the absence of light. Except for a few cases, the room temperature coupling in the dark (thermal process) generally does not work. When it does, it is likely to also involve free carbenes as key intermediates

  据报道可见光促进的光化学方案用于芳基重氮乙酸酯与硼酸的偶联。与没有光照的相同方案相比，这种光化学反应显示出极大的增强。除少数情况外，在黑暗（热过程）中的室温耦合通常不起作用。如果这样做的话，很可能还涉及到游离卡宾作为关键中间体。可替代地，光化学反应显示出广泛的范围，可以在空气中进行并且耐受各种各样的官能团。反应进化监测，DFT计算和控制实验已用于评估这种复杂机制的主要方面。具有生物活性的分子阿迪芬，苯那西嗪和阿普生已经被制备为合成应用的实例。
• Visible‐Light‐Mediated S−H Bond Insertion Reactions of Diazoalkanes with Cysteine Residues in Batch and Flow
  作者：Long‐Zhou Qin、Xin Yuan、Yu‐Sheng Cui、Qi Sun、Xiu Duan、Kai‐Qiang Zhuang、Lin Chen、Jiang‐Kai Qiu、Kai Guo

  DOI：10.1002/adsc.202000716

  日期：2020.11.18

  diazoacetates with cysteine residues that enabled metal‐free, S−H functionalization under visible‐light conditions. Moreover, this process could be intensified by a continuous‐flow photomicroreactor on the acceleration of the reaction (6.5 min residence time). The batch and flow protocols described were applied to obtain a wide range of functionalized cysteine derivatives and cysteine‐containing dipeptides

  我们描述了芳基重氮乙酸酯与半胱氨酸残基的S-H键插入反应的应用，该反应可在可见光条件下实现无金属的S-H功能化。此外，连续反应光微反应器可加快反应速度（6.5分钟的停留时间），从而增强该过程。所描述的批次和流程方案可用于获得各种功能化的半胱氨酸衍生物和含半胱氨酸的二肽，从而为其在温和条件下的功能化提供了一个简单而通用的平台。
• [EN] INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DE NOROVIRUS ET DE CORONAVIRUS
  申请人：COCRYSTAL PHARMA INC

  公开号：WO2021206876A1

  公开（公告）日：2021-10-14

  Compounds of Formula (I) and methods of inhibiting the replication of viruses in a biological sample or patient, of reducing the amount of viruses in a biological sample or patient, and of treating a virus infection in a patient, comprising administering to said biological sample or patient an effective amount of a compound represented by Formula (I), a compound of Table A or B or a pharmaceutically acceptable salt thereof.

  公式（I）化合物及抑制生物样本或患者中病毒复制、减少生物样本或患者中病毒数量、以及治疗患者病毒感染的方法，包括向所述生物样本或患者投与由公式（I）表示的化合物、表A或B中的化合物或其药用可接受盐的有效量。
• [EN] 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS<br/>[FR] DERIVES DE PIPERAZINES 1-ARYL-4-SUSBTITUES UTILISES EN TANT QU'ANTAGONISTES DU CCR1 DANS LE TRAITEMENT DE L'INFLAMMATION ET DES TROUBLES IMMUNITAIRES
  申请人：CHEMOCENTRYX INC

  公开号：WO2003105853A1

  公开（公告）日：2003-12-24

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了作为CCR1受体强效拮抗剂的化合物，并且已经在动物炎症测试中进一步确认，炎症是CCR1的典型疾病状态之一。这些化合物通常是芳基哌嗪衍生物，在制药组合物、治疗CCR1介导疾病的方法以及用于鉴定竞争性CCR1拮抗剂的检测中具有用途。
• Enantioselective Intermolecular Radical C–H Amination
  作者：Li-Mei Jin、Pan Xu、Jingjing Xie、X. Peter Zhang

  DOI：10.1021/jacs.0c10415

  日期：2020.12.9

  noncovalent attractive interactions through fine-tuning of the remote substituents of the D2-symmetric chiral amidoporphyrin ligand. This noncovalent interaction strategy presents a solution that may be generally applicable in controlling reactivity and enantioselectivity in intermolecular radical reactions. The Co(II)-catalyzed intermolecular C-H amination, which operates under mild conditions with the C-H

  自由基反应在有机合成中具有许多固有优势，可能会影响有机分子构建的规划和实践。然而，自由基过程中对映选择性的控制仍然是长期存在的挑战之一。虽然最近在分子内自由基反应方面取得了重大进展，但分子间自由基反应中的不对称诱导的控制仍然提出了具有挑战性的问题。我们在此报告了一种催化方法，该方法通过基于 Co(II) 的金属自由基催化 (MRC) 控制对映选择性以及羧酸酯与有机叠氮化物的分子间自由基 CH 胺化的反应性。成功的关键在于通过微调 D2 对称手性酰胺卟啉配体的远程取代基来最大化非共价吸引力相互作用的催化剂开发。这种非共价相互作用策略提供了一种解决方案，可普遍适用于控制分子间自由基反应的反应性和对映选择性。Co(II) 催化的分子间 CH 胺化反应在温和条件下以 CH 底物为限制试剂，表现出广泛的底物范围和高化学选择性，为获得具有高对映选择性的有价值的手性氨基酸衍生物提供了有效途径。系统的机理研究揭示了基于

表征谱图